- First patient in the world treated with Alpha DaRT ®  in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months – - This pilot study is a key part of Alpha Tau’s broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs - Jerusalem, December 9, 2025 - Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW)

Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026 JERUSALEM, December 4, 2025 -- Alpha Tau Medical Ltd.  ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , announced today that two abstracts have been accepted to the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, to be held

- FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent prostate cancer -   JERUSALEM, December 2, 2025 – Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with locally recurrent prosta

JERUSALEM, December 1, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CFO Raphi Levy will presentation in the following investor conferences in December 2025.   Event: 37th Annual Piper Sandler Healthcare Conference Format: Fireside Chat Date: December 3, 2025 Time: 1:00 – 1:25PM ET Location: New York, NY   Event: Sidoti's Year End Virtual

Dr. Blumenfeld*, what drew you to participate in the Alpha DaRT clinical trial for lung cancer? Alpha DaRT is a very exciting modality with significant potential for the future of radiation oncology. As radiation oncologists, we are always striving to improve what we call the therapeutic ratio: delivering a dose high enough to destroy the tumor while also minimizing harm to healthy tissues. From my experience, Alpha DaRT is unique in its ability to deliver ultra-high, highly